MOA analysis on toxicity and pharmacodynamics of the cardiovascular system adds value in the planning of toxicity mitigation strategies.
Toxic effect on the cardiovascular system is a major factor in the discontinuation of nonclinical drug development due to the risk of sudden death and increased incidence of cardiovascular events.
On the other hand, an unexpected beneficial effect of a compound on the cardiovascular system can potentially add value to a drug.
Axcelead carries out assessments using various evaluation systems for the heart, blood vessels, kidneys, and the central nervous system.
We also conduct MOA analysis of efficacy and toxicity using pharmacological and molecular biological approaches.
Comprehensive assessment→ Identification of functional organs and tissues
Differentiation between On- or Off-target actions
- Preparation and analysis of genetically engineered mice and rats for the target molecule / mice treated with a target molecule viral vector
- Use of selective inhibitors and activators for target molecules
- Estimated from concentrations and pharmacokinetics showing target molecule inhibition/activation in vitro
Identification of Oﬀ-target molecule
- Pharmacological approaches: Explore for changes in intracellular signal transduction, use of receptor antagonists and other drugs, measurement of blood hormones and neurotransmitters, etc.
- Approaches by drug target discovery: Transcriptome analysis (fingerprinting), proteome analysis, etc.
We propose the optimal analysis approach according to your project.